Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Synovial Sarcoma Therapeutic Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for FZD10 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | FZD10 ECD-Fc Fusion Protein (Cysteine-Rich Domain) High purity (>95%), Endotoxin <1EU/ug. HEK293 Expressed for native glycosylation. Sequence Verified. |
View FZD10 Products |
| Gene Delivery | FZD10 Promise-ORF / Lentivirus Full-length FZD10 ORF for stable cell line generation. Ideal for cell-based conformation-sensitive assays. |
View FZD10 Products |
| Benchmark Ab | Anti-FZD10 Recombinant Antibody Sequence derived from clinical benchmark OTSA101. Ideal positive control for binding and internalization assays. |
View FZD10 Products |
| Validator | FZD10 siRNA Set For target knockdown verification and target specificity validation. |
View FZD10 Products |
| Related Target A | WNT7A Synergistic pathway ligand. FZD10 functions as a receptor for Wnt proteins, specifically showing high affinity for WNT7A to drive oncogenic beta-catenin signaling. |
View WNT7A Products |
| Related Target B | LRP6 Essential co-receptor in the Wnt/beta-catenin signaling cascade. Crucial for verifying receptor-complex assembly and blocking assays. |
View LRP6 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Conformational Integrity of 7-TM Protein | Lentivirus-driven stable cell line development ensures native membrane folding and correct extracellular loop presentation. |
| Ligand-Binding Specificity (Wnt Interactions) | Recombinant FZD10 Extracellular Cysteine-Rich Domain (CRD) fused to Fc, expressed in HEK293 with native post-translational modifications. |
| Lack of Reliable Reference Controls | Sequence-verified OTSA101 biosimilar antibody ready for assay calibration and benchmark screening. |
| Target Knockdown Verification | Sequence-specific siRNA pool designed for robust gene silencing to confirm assay specificity. |
Live FZD10 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for FZD10 therapeutics is intensifying, with major players shifting focus from traditional naked monoclonal antibodies to antibody-drug conjugates (ADCs) and radioligand therapies. Because FZD10 is highly overexpressed in synovial sarcoma and other solid tumors (such as gastric, colorectal, and glioblastoma) while maintaining extremely low expression in normal adult tissues, it represents an ideal tumor-associated antigen (TAA). As first-generation therapies reach the clinic, the next wave of R&D is targeting internalization-driven ADC modalities and bispecific T-cell engagers (BiTEs) to maximize tumor-killing potency while minimizing off-target toxicities.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Antibody-Drug Conjugate (ADC) | OncoTherapy Science, Academic Institutions | Synovial Sarcoma, Colorectal Cancer | Internalization Assay (Need high-purity ECD-Fc and stable FZD10-expressing cell lines) |
| Radiolabeled Antibody | OncoTherapy Science (OTSA101-Y90) | Synovial Sarcoma | Epitope mapping & high-affinity binding verification (Need native CRD conformation) |
| CAR-T / Cell Therapy | Biotech Startups, Translational Research Groups | Glioblastoma, Solid Tumors | In vitro cytolytic assays (Need FZD10 Lentivirus for stable target cell line construction) |